Neurocrine biosciences presents new kinect®-hd data showing consistent efficacy across 19 subgroups and improvements in aspects of emotional health with ingrezza® (valbenazine) capsules

Data support positive impact of ingrezza in people with huntington's disease chorea findings presented at the 2024 annual meeting of the huntington study group san diego , nov. 7, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presented subgroup analyses and data from the kinect®-hd study showing the impact of ingrezza® (valbenazine) capsules on emotional health and psychiatric stability in patients with chorea associated with huntington's disease. the subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores.
NBIX Ratings Summary
NBIX Quant Ranking